Oxford Biomedica plc (LON:OXB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Brokerages assign Oxford Biomedica a consensus recommendation of Moderate Buy (five buys, one hold) with an average 12‑month price target of GBX 663.67, while recent analyst targets include GBX 950 (Stifel) and GBX 800 (Deutsche Bank).
• The stock recently traded at GBX 637, below its 50‑day SMA (GBX 763.94) and near the 200‑day SMA (GBX 661.39), and has a 52‑week range of GBX 232.50–952; the company has a market cap of £769.95m, a high debt‑to‑equity ratio of 322.11 and a negative P/E (-17.59), indicating losses and elevated leverage.
• Oxford Biomedica is a specialist CDMO in cell and gene therapy with over 25 years of experience in viral vectors (lentivirus, AAV, adenoviral), partnering with pharmaceutical and biotech companies on vector development and manufacturing.

Shares of Oxford Biomedica plc (LON:OXB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is GBX 663.67.

A number of analysts have recently issued reports on OXB shares. Stifel Nicolaus reissued a "buy" rating and set a GBX 950 price objective on shares of Oxford Biomedica in a report on Wednesday. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a "buy" rating in a research note on Friday, January 9th.

Oxford Biomedica Stock Performance

Shares of OXB traded down GBX 14 during trading hours on Wednesday, hitting GBX 637. The company's stock had a trading volume of 135,453 shares, compared to its average volume of 654,885. The business has a 50 day simple moving average of GBX 763.94 and a two-hundred day simple moving average of GBX 661.39. Oxford Biomedica has a 52-week low of GBX 232.50 and a 52-week high of GBX 952. The company has a debt-to-equity ratio of 322.11, a current ratio of 1.89 and a quick ratio of 1.67. The company has a market cap of £769.95 million, a price-to-earnings ratio of -17.59 and a beta of 1.04.

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.